Who cares about pharmacovigilance?

European Journal of Clinical Pharmacology

Volumn 53, Issue 2, 1997, Pages 83-88

  Edwards, I R ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

Drug safety; Pharmacovigilance

Indexed keywords

ADVERSE DRUG REACTION; DATA BASE; DRUG INFORMATION; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; INFORMATION PROCESSING; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANIMALS; ATTITUDE OF HEALTH PERSONNEL; DRUG MONITORING; HUMANS;

EID: 0030727881     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050342     Document Type: Short Survey

References (12)

1. Biriell C, Edwards IR (1997) Reasons for reporting adverse drug reactions - some thoughts based on an international review. Pharmacoepidemiol Drug Safety 6: 21-26
2. Inman WHW (1976) Detection and investigation of drug safety problems. In: Gent M, Shigamatsu I (eds). Epidemiological issues in reported drug-induced illnesses. Honolulu 1976. McMaster University Library Press, Hamilton, Ontario
3. Koch-Weser J, Sidel VW, Sweet RH, Kanarek P, Eaton AE (1969) Factors determining physician reporting of adverse drug reactions. Comparison of 2000 spontaneous reports with surveillance studies at the Massachusetts General Hospital. N Engl J Med 280: 20-26
4. Bateman DN, Sanders GL, Rawlins MD (1992) Attitudes to adverse drug reaction reporting in the Northern Region. Br J Clin Pharmacol 34: 421-426
5. Belton KJ, Lewis SC, Payne S, Rawlins M (1995) Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom. Br J Clin Pharmacol 39: 223-226
6. Inman WHW, Rawson NSB, Wilton LV (1986) Prescription event monitoring. In: Monitoring for drug safety, 2nd edn., MTP Press, Lancaster, England pp 213-236
7. Coulter DM, Edwards IR, McQueen EG (1986) Post marketing surveillance in the general population New Zealand. In: Monitoring for drug safety, 2nd edn: MTP Press, Lancaster, England, pp 119-134
8. Lindquist M, Sanderson J, Claesson C, Imbs J-L, Rohan A, Edwards IR (1994) New pharmacovigilance information on an old drug - an international study of spontaneous reports on digoxin. Drug Invest 8: 73-80
9. Clark DJW, Edwards IR (1988) Adverse drug reactions and phenotyping of ocidation polymorphism. Med Toxicol 3: 241-247
10. The ADR signals analysis project (ASAP) team: (Lindquist M, Pettersson M, Edwards IR, Sanderson J, Taylor N, Fletcher P, Schou J), Fraunfelder FT (1996) Omeprazole and visual disorders: seeing alternatives. Pharmacoepidemiol Drug Safety 5: 27-32
11. Edwards IR, Wiholm B-E, Martinez C (1996) Concepts in risk benefit assessment. Drug Safety 15: 1-7
12. McNamee D (1996) Speaking about pharmacovigilance. Lancet 348: 908